Omanta
Omanta operates as a personal research laboratory for patients with complex, rare, or treatment-resistant conditions, assigning a dedicated PhD-level scientific team to each case. The company builds a detailed molecular profile using whole-genome sequencing, single-cell RNA analysis, and spatial proteomics, then cross-references findings against a 5,000-sample internal reference cohort to guide clinical decisions.
- Healthcare Technology
- Biotechnology
- Data & Analytics
Funding
Raised to date
$500KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Complex and rare disease patients often fall through the cracks of standard clinical care, where diagnostic workups are limited to routine tests and population-averaged treatment protocols. These patients face prolonged diagnostic odysseys, fragmented records across multiple specialists, and a lack of dedicated scientific attention to their unique molecular biology.
Solution
Omanta provides each complex patient with a dedicated PhD-level research team that functions as a personal laboratory. The team collects and organizes all patient evidence—records, imaging, pathology, and molecular data—then closes diagnostic gaps by coordinating additional testing. Using advanced technologies including whole-genome sequencing, bulk and single-cell RNA sequencing, and spatial proteomics, Omanta builds a detailed molecular profile of the disease. Each case is cross-referenced against Omanta's internal 5,000-sample reference cohort to interpret signals in population context. The team then connects the patient's biology to published evidence and clinical trials, ultimately working alongside the patient's physicians to translate findings into real clinical decisions.
Target Audience
Primary customers are individual patients with complex, rare, or treatment-resistant conditions, as well as their treating physicians who seek deeper scientific investigation beyond routine diagnostics.
Features
- Dedicated PhD-level case team selected specifically for the biology and questions unique to each patient's condition
- Multi-omics profiling combining whole-genome sequencing, whole-exome sequencing, copy-number variation, and tumor mutational burden analysis
- RNA analysis capabilities including bulk, short-read, long-read, single-cell RNA sequencing, and spatial transcriptomics
- Protein-level analysis via immunohistochemistry, multiplex immunofluorescence, and mass-spectrometry proteomics
- Case-to-cohort comparison against an internal 5,000-sample reference dataset to contextualize molecular findings
- Therapeutic evidence modeling that cross-references patient genomics with structured efficacy, safety, and side-effect data to assess potential benefit and risk
- Three connected evidence layers integrating internal reference data, biomedical research, and clinical trial information for mechanistic interpretation